XTX Topco Ltd raised its holdings in Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) by 54.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,198 shares of the biopharmaceutical company’s stock after buying an additional 8,841 shares during the period. XTX Topco Ltd’s holdings in Dynavax Technologies were worth $281,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Dynavax Technologies by 1.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 1,172 shares during the last quarter. SummerHaven Investment Management LLC grew its position in shares of Dynavax Technologies by 2.4% in the second quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 1,303 shares during the last quarter. Nisa Investment Advisors LLC grew its position in shares of Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,679 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Dynavax Technologies by 175.5% in the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,685 shares during the last quarter. Finally, Louisiana State Employees Retirement System grew its position in shares of Dynavax Technologies by 3.0% in the second quarter. Louisiana State Employees Retirement System now owns 65,900 shares of the biopharmaceutical company’s stock valued at $740,000 after purchasing an additional 1,900 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th.
Dynavax Technologies Trading Up 0.4 %
Shares of NASDAQ:DVAX opened at $12.90 on Wednesday. The company has a market capitalization of $1.70 billion, a P/E ratio of 99.23 and a beta of 1.33. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $15.01. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The business’s 50 day simple moving average is $12.06 and its 200 day simple moving average is $11.49.
About Dynavax Technologies
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Articles
- Five stocks we like better than Dynavax Technologies
- How to Effectively Use the MarketBeat Ratings Screener
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- Stock Average Calculator
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Salesforce’s Clear Path to $400 and Beyond
Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX – Free Report).
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.